{"id":"tp-40938","type":"article-newspaper","title":"Eli Lilly’s Olomorasib Posts a 62% Response Rate in Lung Cancer Study","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/40938","datePublished":"2026-10-26T10:50:39.000Z","dateModified":"2026-10-26T10:50:39.000Z","language":"en","abstract":"The 77-patient combination group had median progression-free survival of 11.6 months. First randomized Phase 3 data are expected in the first half of 2027.","section":"Business","references":[]}